Conmed Corp CNMD Stock Analysis
- NYSE
- Stock
- Market closed · opens Monday 9:30 AM ET
$46.72 down $0.42, 0.89% at close Oct 16
Last close · Previous close $47.14
- Market cap
- $1.41BAt the Oct 16 close
- P/E ratio
- 25.25On last 12 months’ EPS
- Diluted EPS
- $1.85Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$46.72down $0.42, 0.89%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$47.14Oct 15
- Volume413.97KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume400.53KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $31.44 to $53.66; now $46.72
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CNMD beat the S&P 500 in 2 of 7 periods.
| Period | CNMD and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CNMD: down 0.7% S&P 500: up 1.5% | CNMD trailed the S&P 500 by 2.2 percentage points Trailed |
| 3M | CNMD: up 3.8% S&P 500: up 1.9% | CNMD beat the S&P 500 by 1.9 percentage points Beat |
| YTD | CNMD: up 15.1% S&P 500: up 12.8% | CNMD beat the S&P 500 by 2.3 percentage points Beat |
| 1Y | CNMD: up 3.9% S&P 500: up 16.8% | CNMD trailed the S&P 500 by 12.9 percentage points Trailed |
| Long term | ||
| 3Y | CNMD: down 49.7% S&P 500: up 81.5% −20.5% vs +22.0% a year | CNMD trailed the S&P 500 by 131.2 percentage points Trailed |
| 5Y | CNMD: down 65.8% S&P 500: up 83.1% −19.3% vs +12.9% a year | CNMD trailed the S&P 500 by 148.9 percentage points Trailed |
| 10Y | CNMD: up 30.9% S&P 500: up 319.6% +2.7% vs +15.4% a year | CNMD trailed the S&P 500 by 288.7 percentage points Trailed |
$10,000 invested in CNMD 10 years ago (Oct 14, 2016) would be worth about $13,091 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
CNMD beat the S&P 500 in 2 of 7 periods.
| Period | CNMD and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CNMD: down 0.7% S&P 500: up 1.2% | CNMD trailed the S&P 500 by 1.9 percentage points Trailed |
| 3M | CNMD: up 3.8% S&P 500: up 1.7% | CNMD beat the S&P 500 by 2.1 percentage points Beat |
| YTD | CNMD: up 15.1% S&P 500: up 11.9% | CNMD beat the S&P 500 by 3.2 percentage points Beat |
| 1Y | CNMD: up 3.9% S&P 500: up 15.5% | CNMD trailed the S&P 500 by 11.6 percentage points Trailed |
| Long term | ||
| 3Y | CNMD: down 50.9% S&P 500: up 75.0% −21.1% vs +20.5% a year | CNMD trailed the S&P 500 by 125.9 percentage points Trailed |
| 5Y | CNMD: down 67.1% S&P 500: up 71.2% −19.9% vs +11.4% a year | CNMD trailed the S&P 500 by 138.3 percentage points Trailed |
| 10Y | CNMD: up 19.2% S&P 500: up 258.1% +1.8% vs +13.6% a year | CNMD trailed the S&P 500 by 238.9 percentage points Trailed |
$10,000 invested in CNMD 10 years ago (Oct 14, 2016) would be worth about $11,915 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$157.03
Closing high on . Now 70.2% below that record.
Split-adjusted daily closes since Mar 26, 1990.
Stock splits
3
Latest: 3-for-2 on . One share bought before the first split is 3 shares today.
All 3 splits
- 3-for-2
- 3-for-2
- 3-for-2
Valuation
The Oct 16 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
25.3×The Oct 16 close ÷ diluted EPS over the last 12 months ($1.85)
The range covers daily P/E ratios from Oct 8, 2021 to Oct 16, 2026, each based on the previous 12 months of earnings.
CNMD trades at 25.3× its earnings over the last 12 months, above its 5-year median of 25.1×. In plain terms, buyers are paying about $25 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 1.0×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 1.4×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 17.0×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - 9.56%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $2.20BAt the Oct 16 close
What it would cost to buy the whole business: the market cap at the Oct 16 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own CNMD DCF in Excel. Value Conmed with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $1.37Bup 3.4%
- Net income
- $56.50Mdown 48.7%
- Diluted EPS
- $1.85down 47.6%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $316.70M | $48.98M | $1.57 |
| Q4 FY24 (Dec 31, 2024) | $345.94M | $33.76M | $1.08 |
| Q1 FY25 (Mar 31, 2025) | $321.26M | $6.04M | $0.19 |
| Q2 FY25 (Jun 30, 2025) | $342.35M | $21.42M | $0.69 |
| Q3 FY25 (Sep 30, 2025) | $337.93M | $2.86M | $0.09 |
| Q4 FY25 (Dec 31, 2025) | $373.20M | $16.74M | $0.54 |
| Q1 FY26 (Mar 31, 2026) | $317.05M | $13.83M | $0.45 |
| Q2 FY26 (Jun 30, 2026) | $343.49M | $23.07M | $0.77 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $1.01B | $62.54M | $1.94 |
| FY22 (Dec 31, 2022) | $1.05B | −$80.58M | −$2.68 |
| FY23 (Dec 31, 2023) | $1.24B | $64.46M | $2.04 |
| FY24 (Dec 31, 2024) | $1.31B | $132.42M | $4.25 |
| FY25 (Dec 31, 2025) | $1.37B | $47.06M | $1.51 |
Margins
- Gross 55.8%
- Operating 8.0%
- Net 4.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $134.46MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$150.59MLast 12 months
- Capital spending$16.12MLast 12 months
- 9.8%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $43.22MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$12.38MLast 12 months
- Total returned$55.60MLast 12 months
41% of free cash flow
Balance sheet
- $37.33MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$834.25MAs of Jun 30, 2026
- Net debt$796.92MAs of Jun 30, 2026
- 1.48As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.80As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 6 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✓Share count didn’t rise: passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 5.5%Last 12 months
Over the last 12 months, Conmed’s net income was 5.5% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 2.4%Last 12 months
Over the last 12 months, Conmed’s net income was 2.4% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $0.80 |
| 2017 | $0.80 |
| 2018 | $0.80 |
| 2019 | $0.80 |
| 2020 | $0.80 |
| 2021 | $0.80 |
| 2022 | $0.80 |
| 2023 | $0.80 |
| 2024 | $0.80 |
| 2025 | $0.60 |
| 2026 (to date) | $0.000 |
Dividend details
- $0.00Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- 0.00%; 5-yr low 0.39%, 5-yr high 2.05%Last 12 months
Dividends paid over the last 12 months as a share of the Oct 16 close. The bar shows where that yield sits in its range over the past five years; the median was 0.96%.
- $0.20Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
About Conmed Corp
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- New York, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
CNMD news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CNMD stock FAQ
What is CNMD stock’s price today?
Conmed (CNMD) traded at $46.72 at the close on , down $0.42 (0.89%) from the previous close of $47.14. Over the past 52 weeks it has traded between $31.44 and $53.66.
If you invested $1,000 in CNMD 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CNMD on would be worth about $1,309 at the close on , a total return of +30.9%. The same $1,000 would be worth $342 if invested five years ago, $1,039 if invested one year ago, $2,553 if invested 20 years ago, and $4,883 if invested 30 years ago. Past performance doesn’t predict future returns.
What is Conmed’s market cap?
Conmed’s market capitalization is about $1.4 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $46.72 (how market cap works). Conmed reported 30.11M shares outstanding at the end of its latest quarter ().
What is CNMD’s P/E ratio?
CNMD trades at 25.3 times its diluted earnings over the four quarters to ($1.85 per share), at the close. Over the past five years its P/E has ranged from 12.4 to 73.6, with a median of 25.1. (How the P/E ratio works.)
How much revenue does Conmed make?
Conmed reported $1.4 billion of revenue over the four quarters to , up 3.4% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $343.5 million, up 0.3% from a year earlier.
Is Conmed profitable?
Yes. Conmed earned $56.5 million of net income over the four quarters to , a net margin of 4.1%, and its operating margin was 8.0% (what margins tell you).
What are CNMD’s earnings per share?
CNMD’s diluted earnings per share were $1.85 over the four quarters to , compared with $3.53 in the twelve months before. The latest quarter (Q2 FY26) brought $0.77 per share, against $0.69 a year earlier (how EPS works).
Does CNMD pay a dividend?
Conmed hasn’t paid a dividend in the last twelve months.
What is CNMD’s 52-week high and low?
Over the past 52 weeks CNMD has traded as low as $31.44 and as high as $53.66. At $46.72 at the close on , it is 12.9% below that high and 48.6% above the low.
What is CNMD’s all-time high?
CNMD’s highest closing price was $157.03 on , adjusted for stock splits. At $46.72 at the close on , it is 70.2% below that record.
Has CNMD stock ever split?
Yes, three times: 3-for-2 on ; 3-for-2 on ; 3-for-2 on . One share bought before the first split would be 3 shares today.
How has CNMD stock performed?
Including dividends and measured to the close on , CNMD has returned +15.1% so far this year and +3.9% over the past year, and −65.8% over five years (−19.3% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Conmed in?
Conmed is in the Healthcare sector and the Medical Devices industry, and is headquartered in New York, USA.
What exchange does CNMD trade on?
Conmed trades on the NYSE under the ticker symbol CNMD. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.